|
Hepatitis E Virus
1. Name of the Organism:
Hepatitis E Virus |
Hepatitis E Virus (HEV) has a particle diameter of 32-34 nm, a buoyant density of 1.29 g/ml in KTar/Gly gradient, and is very labile. Serologically related smaller (27-30 nm) particles are often found in feces of patients with Hepatitis E and are presumed to represent degraded viral particles. HEV has a single-stranded polyadenylated RNA genome of approximately 8 kb. Based on its physicochemical properties it is presumed to be a calici-like virus. |
2. Nature of Acute Disease: | The disease caused by HEV is called
hepatitis E, or enterically transmitted non-A non-B
hepatitis (ET-NANBH). Other names include fecal-oral
non-A non-B hepatitis,and A-like non-A non-B hepatitis. Note: This disease should not be confused with hepatitis C, also called parenterally transmitted non-A non-B hepatitis (PT-NANBH), or B-like non-A non-B hepatitis, which is a common cause of hepatitis in the U.S. |
3. Nature of Disease: | Hepatitis caused by HEV is clinically indistinguishable from hepatitis A disease. Symptoms include malaise, anorexia, abdominal pain, arthralgia, and fever. The infective dose is not known. |
4. Diagnosis of Human Illness: | Diagnosis of HEV is based on the epidemiological characteristics of the outbreak and by exclusion of hepatitis A and B viruses by serological tests. Confirmation requires identification of the 27-34 nm virus-like particles by immune electron microscopy in feces of acutely ill patients. |
5. Associated Foods: | HEV is transmitted by the fecal-oral route. Waterborne and person-to-person spread have been documented. The potential exists for foodborne transmission. |
6. Relative Frequency of Disease: | Hepatitis E occurs in both epidemic and sporadic-endemic forms, usually associated with contaminated drinking water. Major waterborne epidemics have occurred in Asia and North and East Africa. To date no U.S. outbreaks have been reported. |
7. Course of Disease and Complications: | The incubation period for hepatitis E varies from 2 to 9 weeks. The disease usually is mild and resolves in 2 weeks, leaving no sequelae. The fatality rate is 0.1-1% except in pregnant women. This group is reported to have a fatality rate approaching 20%. |
8. Target Populations: | The disease is most often seen in young to middle aged adults (15-40 years old). Pregnant women appear to be exceptionally susceptible to severe disease, and excessive mortality has been reported in this group. |
9. Food Analysis: | HEV has not been isolated from foods. No method is currently available for routine analysis of foods. |
10. Selected Outbreaks: | Literature references can be found at the links below. |
Major waterborne epidemics have occurred in India (1955 and 1975-1976), USSR (1955-1956), Nepal (1973), Burma (1976-1977), Algeria (1980-1981), Ivory Coast (1983-1984), and most recently in Borneo (1987). To date, no outbreak has occurred in the U.S., but imported cases were identified in Los Angeles in 1987. There is no evidence for immunity against this agent in the American population. Thus, unless other factors (such as poor sanitation or prevalence of other enteric pathogens) are important, the potential for spread to the U.S. is great. Good sanitation and personal hygiene are the best preventive measures. | |
MMWR 36(36):1987 | Two outbreaks of enterically transmitted non-A, non-B (ET-NANB) hepatitis occurred during the late summer and fall of 1986 in rural villages in the State of Morelos, Mexico. This is the first reported instance of epidemic transmission of this disease in the Americas. |
MMWR 36(16):1987 | Outbreaks of enterically transmitted non-A, non-B hepatitis occurred in 1985 and 1986 at refugee camps for Ethiopians in Somalia and the Sudan. |
Morbidity and Mortality Weekly Reports | For more information on recent outbreaks see the CDC. |
11. Education and Background Resources: | Literature references can be found at the links below. |
Loci index for genome Hepatitis E | Available from the GenBank Taxonomy database, which contains the names of all organisms that are represented in the genetic databases with at least one nucleotide or protein sequence. |
12. Molecular Structural Data: | None currently available. |
mow@cfsan.fda.gov
January 1992 with periodic updates
Foods Home | FDA Home | Search/Subject Index | Disclaimers & Privacy Policy | Accessibility/Help
Hypertext last updated by las/ear 2002-FEB-13